Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Desvenlafaxine
Drug ID BADD_D00621
Description Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin norepinephrine reuptake inhibitor (SNRI) class[Label]. Desvenlafaxine may be used to treat major depressive disorder[Label]. It is formulated as an extended release tablet[Label]. Desvenlafaxine was approved by the FDA in 2008[L6016].
Indications and Usage Desvenlafaxine is indicated for the treatment of major depressive disorder in adults[A6990,A6991,Label].
Marketing Status approved; investigational
ATC Code N06AX23
DrugBank ID DB06700
KEGG ID D07793
MeSH ID D000069468
PubChem ID 125017
TTD Drug ID D0O3FG
NDC Product Code 63304-191; 0054-0401; 0054-0603; 14501-0068; 70436-013; 70771-1311; 68382-469; 0054-0400; 70436-036; 70771-1312; 0591-3660; 71335-1815; 68382-105; 46708-152; 70518-3195; 69766-025; 60687-607; 63304-192; 70771-1661; 68382-741; 72888-144; 46708-153; 53002-1801; 71335-1753; 71335-1975; 72888-143; 63629-7524; 70436-012; 0591-3659; 71335-1700; 0591-4060; 50090-4806
UNII NG99554ANW
Synonyms Desvenlafaxine Succinate | Succinate, Desvenlafaxine | O-desmethylvenlafaxine Succinate Monohydrate | Monohydrate, O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate Monohydrate | Succinate Monohydrate, O-desmethylvenlafaxine | 2-(1-hydroxycyclohexyl)-2-((4-hydroxyphenyl)ethyl)dimethylammonium 3-carboxypropanoate monohydrate | O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate | Succinate, O-desmethylvenlafaxine | WY 45,233 | 45,233, WY | WY-45,233 | WY45,233 | WY-45233 | WY45233 | WY 45233 | 45233, WY | Pristiq | Desvenlafaxine | O-desmethylvenlafaxine | O desmethylvenlafaxine | 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol
Chemical Information
Molecular Formula C16H25NO2
CAS Registry Number 93413-62-8
SMILES CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Photosensitivity reaction23.03.09.0030.000392%
Pre-existing condition improved08.01.03.0430.000784%Not Available
Productive cough22.02.03.0050.000695%
Proteinuria20.02.01.011--
Psychotic behaviour19.03.01.0030.000267%Not Available
Rash23.03.13.001--Not Available
Respiratory disorder22.02.07.0020.000392%Not Available
Restlessness19.11.02.002; 17.02.05.0210.001444%
Retching07.01.07.0020.000606%Not Available
Rhinorrhoea22.12.03.0210.000392%
Screaming19.04.02.020; 08.01.03.0990.000481%Not Available
Sedation17.02.04.0050.000267%Not Available
Seizure17.12.03.0010.001605%
Serotonin syndrome17.05.02.004; 15.05.04.016; 12.03.01.0410.000802%Not Available
Sexual dysfunction21.03.02.003; 19.08.05.0020.002817%Not Available
Shock24.06.02.0020.000178%Not Available
Sinus headache22.12.03.022; 17.14.01.0020.000909%
Skin disorder23.03.03.007--Not Available
Skin reaction23.03.03.013; 10.01.03.0190.000392%Not Available
Sleep disorder19.02.04.0010.000660%Not Available
Sleep terror17.15.02.006; 19.02.03.0080.000606%Not Available
Sluggishness08.01.01.0040.000606%Not Available
Somnambulism19.02.03.006; 17.15.02.004--Not Available
Somnolence19.02.05.003; 17.02.04.0060.002781%
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.0030.000535%Not Available
Stevens-Johnson syndrome11.07.01.005; 10.01.01.045; 23.03.01.007; 12.03.01.014--
Stress19.06.02.0040.001177%Not Available
Suicidal ideation19.12.01.0030.004992%
Suicide attempt19.12.01.0040.000802%
Swollen tongue07.14.02.003; 23.04.01.014; 10.01.05.0150.000481%Not Available
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 11 Pages